DOI: 10.4274/tjh.2015.0416 Turk J Hematol 2017;34:120-121

Griscelli Syndrome Presented with Status Epilepticus and Hemophagocytic Lymphohistiocytosis

Status Epileptikus ve Hemofagositik Lenfohistiyositoz ile Başvuran Griscelli Sendromu

Fatih Demircioğlu¹, Hilal Avdın², Mustafa Erkocoğlu³, Hüsevin Önav⁴, Emine Dağıstan⁵

⁵Abant İzzet Baysal University Faculty of Medicine, Department of Radiology, Bolu, Turkey




Figure 1. (a) Partial albinism with silvery gray hair. (b) Bone marrow examination showing hemophagocytosis. (c) Hair examination showing irregularly scanty melanin pigments.




Figure 2. Griscelli syndrome: cerebral involvement. (a) Axial T1weighted magnetic resonans (MR) image shows bilateral lowsignal-intensity areas in white matter of cerebellum. (b) Axial fluid attenuation inversion recovery MR image demonstrates high-signal-intensity in this area. (c) Axial T2-weighted MR image at lateral ventricle level. (d, e) Axial and coronal T2-weighed images showing cerebral atrophy and diffuse high-signalintensity in cerebral white matter. (f) Contrast-enhanced coronal T1-weighted MR image demonstrates no contrast uptake.

A 12-month-old female infant was referred to our hospital with prolonged fever and status epilepticus. Her weight and height were below the 5th percentile for age. Physical examination revealed marked hypotonia, fever, pallor, partial albinism with silvery gray hair, and hepatosplenomegaly (Figure 1A). Laboratory investigations showed anemia, thrombocytopenia, hypofibrinogenemia, hyperferritinemia, and hemophagocytosis at bone marrow examination (Figure 1B).

Lymphocyte subsets and serum immunoglobulin levels were normal. Hair examination showed irregularly scanty melanin pigments (Figure 1C). Electroencephalographic study revealed encephalopathic findings, including decreased background activity with continuous slow wave discharges. Brain magnetic resonance imaging showed diffuse cerebral involvement (Figure 2). RAB27A encoding gene C.149delG mutation was detected. We diagnosed Griscelli syndrome (GS) with

©Copyright 2017 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House



Address for Correspondence/Yazışma Adresi: Fatih DEMİRCİOĞLU, M.D.

Received/Geliş tarihi: January 15, 2015

Abant İzzet Baysal University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Bolu, Turkey Accepted/Kabul tarihi: December 03, 2015
Phone: +90 374 270 45 75-3463

E-mail: fatih_demircioglu@yahoo.com

¹Abant İzzet Baysal University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Bolu, Turkey

²Abant İzzet Baysal University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Neurology, Bolu, Turkey

³Abant İzzet Baysal University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Immunology and Allergy, Bolu, Turkey

⁴Ege University Faculty of Medicine, Department of Molecular Biology and Genetics, İzmir, Turkey

hemophagocytic lymphohistiocytosis (HLH). She received the HLH-2004 treatment protocol. The patient showed complete hematological response to treatment and was discharged after 1 month with persistent neurological involvement. Although bone marrow transplantation is the only curative therapy for GS, we did not plan bone marrow transplantation due to the severe neurological sequela. The patient died due to progressive disease after 6 months.

GS is an autosomal recessive disorder characterized by the silvery gray sheen of the hair and hypopigmentation of the skin, which can be associated with neurological impairment, psychomotor retardation, HLH, and immunodeficiency [1]. Both GS and Chediak-Higashi syndrome may present with oculocutaneous albinism, neutropenia, immune dysfunction, and accelerated phase. In differential diagnosis, the absence of bleeding disorders and giant granules in leukocytes, and finally gene analysis, helped us to exclude Chediak-Higashi syndrome [2]. GS type 1 is caused by a mutation in the *myosin Va* (*MYO5A*) gene, GS type 2 is caused by mutations in the *RAB27A* encoding gene, and GS type 3 is due to mutations in the *MLPH* gene, which forms a protein complex with Rab27a and myosin Va [3,4]. Hematopoietic stem cell transplantation is the only curative treatment for GS with HLH [3,4].

Keywords: Children, Griscelli syndrome, Status epilepticus, Hemophagocytic lymphohistiocytosis

Anahtar Sözcükler: Çocuk, Griscelli sendromu, Status epileptikus, Hemofagositik lenfohistiyositoz

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

- 1. Patıroğlu T, Özdemir MA, Patıroğlu TE. Griscelli's syndrome: clinical and immunological features of two siblings. Turk J Hematol 2000;17:85–87.
- Dotta L, Parolini S, Prandini A, Tabellini G, Antolini M, Kingsmore SF, Badolato R. Clinical, laboratory and molecular signs of immunodeficiency inpatients with partial oculo-cutaneous albinism. Orphanet J Rare Dis 2013;8:168.
- Aslan D, Sari S, Derinöz O, Dalgiç B. Griscelli syndrome: description of a case with Rab27A mutation. Pediatr Hematol Oncol 2006;23:255-261.
- 4. Meeths M, Bryceson YT, Rudd E, Zheng C, Wood SM, Ramme K, Beutel K, Hasle H, Heilmann C, Hultenby K, Ljunggren HG, Fadeel B, Nordenskjöld M, Henter JI. Clinical presentation of Griscelli syndrome type 2 and spectrum of *RAB27A* mutations. Pediatr Blood Cancer 2010;54:563–572.